APA (7th ed.) Citation

Penson, R. T., Huang, H. Q., Wenzel, L. B., Monk, B. J., Stockman, S., Long 3rd, H. J., . . . Long, H. J. 3. (2015). Bevacizumab for advanced cervical cancer: Patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology, 16(3), 301. https://doi.org/10.1016/S1470-2045(15)70004-5

Chicago Style (17th ed.) Citation

Penson, Richard T., et al. "Bevacizumab for Advanced Cervical Cancer: Patient-reported Outcomes of a Randomised, Phase 3 Trial (NRG Oncology-Gynecologic Oncology Group Protocol 240)." Lancet Oncology 16, no. 3 (2015): 301. https://doi.org/10.1016/S1470-2045(15)70004-5.

MLA (9th ed.) Citation

Penson, Richard T., et al. "Bevacizumab for Advanced Cervical Cancer: Patient-reported Outcomes of a Randomised, Phase 3 Trial (NRG Oncology-Gynecologic Oncology Group Protocol 240)." Lancet Oncology, vol. 16, no. 3, 2015, p. 301, https://doi.org/10.1016/S1470-2045(15)70004-5.